Janus kinase and calcineurin‐inhibitor combination in anti‐MDA5 dermatomyositis: No significant survival benefit but reassuring safety profile

JAK-CNI showed a similar outcome to other immunosuppressive combinations. However, as the study included the most severe cases, the potential benefit of early JAK-CNI introduction in less severe forms cannot be dismissed, as suggested by the nonsignificant trend in non-ICU patients. Future studies are needed to clarify the optimal timing and patient selection for JAK-CNI therapy in anti-MDA5 DM.

Authors

Institutions

Publication Details

Journal
Journal of Internal Medicine
Published
2025-11-24
DOI
https://doi.org/10.1111/joim.70047
Primary Topic
Inflammatory Myopathies and Dermatomyositis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Janus kinase and calcineurin‐inhibitor combination in anti‐MDA5 dermatomyositis: No significant survival benefit but reassuring safety profile

B. Hervier, Nicol Cornelia Voermans, Thierry Marhadour, David Launay et al.
Journal of Internal Medicine
Inflammatory Myopathies and Dermatomyositis
article

Janus kinase and calcineurin‐inhibitor combination in anti‐MDA5 dermatomyositis: No significant survival benefit but reassuring safety profile

B. Hervier, Nicol Cornelia Voermans, Thierry Marhadour, David Launay, T. Papo, Charles Cerf, Baptiste Dilly, P Loiseau, Pascaline Priou, Maxime Samson, Yves Allenbach, Benjamin Thoreau, Marine Lemaître, Y. Uzunhan, Olivier Benvéniste, Claire Le Pendu, N. Schleinitz, Alain Meyer, Audrey Ullmer, B. Suzon, A. Renaud, A. Bérezné, Laure Gallay, Hilario Nunès, Laurent Gilardin, Juliette Woessner, L. Pacoureau, Valentine Pagis, Noémie Gensous, Pierre Charles, T. Carmoi, Quentin Astouati, Mickaël Martin, Nicolas Baillet, S. Humbert, Wladimir Mauhin, Élodie Blanchard, Mathilde Neuville, A. Mékinian, Pierre Bay, Antoine Roux, Benjamin Terrier, Thomas Quéméneur, Luc de Saint Martin, Amélie Servettaz, Yann Nguyen, Vincent Cottin, Erwan Oehler
article en

Abstract

JAK-CNI showed a similar outcome to other immunosuppressive combinations. However, as the study included the most severe cases, the potential benefit of early JAK-CNI introduction in less severe forms cannot be dismissed, as suggested by the nonsignificant trend in non-ICU patients. Future studies are needed to clarify the optimal timing and patient selection for JAK-CNI therapy in anti-MDA5 DM.

Journal of Internal MedicineVol. 299(2)
Université de Tours (FR), Tufts University (US), Hôpital américain de paris (FR), Radboud University Nijmegen (NL), Université de Bordeaux (FR), Inserm (FR), Délégation Paris 7 (FR), Lyon College (US), Université Paris-Est Créteil (FR), Université d'Avignon et des Pays de Vaucluse (FR), Université Paris Cité (FR), Aix-Marseille Université (FR), Université de Lille (FR), Terre des Hommes (CH), American University of Paris (FR), Hôpital Beaujon (FR), Saint Louis University Hospital (US), Radboud University Medical Center (NL), Centre Hospitalier Universitaire de Nice (FR), Centre Hospitalier Universitaire de Nantes (FR), Université de Poitiers (FR), Sorbonne Université (FR), Centre Hospitalier Universitaire de Besançon (FR), Université Sorbonne Paris Nord (FR), Institute Mutualiste Montsouris (FR), Hôpital Cochin (FR), Centre Hospitalier Universitaire de Tours (FR), Centre Hospitalier Universitaire Amiens-Picardie (FR), Assistance Publique – Hôpitaux de Paris (FR), Bordeaux Population Health (FR), Hôpital Lyon Sud (FR), Groupe Hospitalier Diaconesses Croix Saint-Simon (FR), Laboratoire Informatique d'Avignon (FR), Pitié-Salpêtrière Hospital (FR), Hôpital Robert-Debré (FR), Centre Hospitalier Régional Universitaire de Brest (FR), Centre Hospitalier Annecy Genevois (FR), Centre de Recherche Saint-Antoine (FR), Centre Hospitalier Universitaire de Martinique (MQ), Centre Hospitalier Victor Dupouy (FR), Institut de Neurosciences de la Timone (FR), Maison des Sciences sociales et des Humanités de Dijon (FR), Hôpital Saint-Louis (FR), Hôpital Bichat-Claude-Bernard (FR), Centre Hospitalier René-Dubos (FR), Hôpital Jean-Verdier (FR), Centre Hospitalier de Valenciennes (FR), Hôpital Foch (FR), Institut Mondor de Recherche Biomédicale (FR), Hôpital de la Timone (FR), Bicêtre Hospital (FR), Université d'Angers (FR), Université Lille Nord de France (FR), Université de Strasbourg (FR), University of French Polynesia (PF), Nantes Université (FR)
Openalex Percentile: Top 53%
Inflammatory Myopathies and Dermatomyositis
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.